E. Sallan, "Anthracycline- induced cardiotoxicity: natural history, risk factors, and prevention," in American Society of Clinical Oncology, Chicago, Ill, USA, 2008.Barry EV, Lipshultz SE, Sallan SE. Anthracycline-induced cardiotoxicity: natural history, risk factors, and preve...
Taken together, dexrazoxane is unlikely to increase secondary malignancy risk. Beta-blockers, ACE inhibitors, or ARBs Beta-blockers, ACE inhibitors, and ARBs were evaluated in randomized controlled trials for primary prevention of anthracycline-induced cardiotoxicity (Table 3). LVEF dropped ...
3.1. Acute anthracycline-induced cardiotoxicity Acute anthracycline-induced cardiotoxicity is defined as a reversible depression of myocardial function after the initial infusion of anthracycline. Discontinuation of the anthracycline usually results in significant improvement. Identification of risk factors is not...
Prevention and treatment of anthracycline-induced cardiotoxicity with enalapril, carvedilol and statins are conceivable strategies to reduce the cardiovascular risk. Statins exhibit anti-inflammatory as well as anti-fibrotic properties and interfere with at least two of the suggested main mechanisms involved ...
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers Christian Henninger*1 and Gerhard Fritz1 Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully ...
Prevention of anthracycline-induced cardiotoxicity, while maintaining the drugs’ therapeutic effectiveness, can be achieved by pharmacological and non-pharmacological means. Non-pharmacological prevention Cardiovascular risk factors should be identified and treated appropriately as soon as cancer is diagnosed. ...
No patient with 10–15% decline in EF during therapy developed cardiotoxicity. Younger age (P = 0.004) and low BMI (P = 0.034) as continuous variables with anthracycline administration by IV push (P = 0.03) were risk factors for cardiotoxicity on univariate analysis but not ...
Preclinical and clinical studies suggest that anthracycline-induced cardiotoxicity can be prevented by administering coenzyme Q10 during cancer chemotherap... KA Conklin - 《Integrative Cancer Therapies》 被引量: 202发表: 2005年 Genotyping the risk of anthracycline-induced cardiotoxicity Anthracyclines belong...
anthracycline‐induced cardiotoxicitycancerchemotherapyclinical practice guidelinescongestive heart failurepharmacogenomic screeningPURPOSECardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer...
[61]. They concluded that high baseline immunoglobulin E levels were associated with a significantly lower risk of doxorubicin/trastuzumab-induced cardiac dysfunction. These findings implicate the immune system in doxorubicin-induced cardiotoxicity, an angle that has not been considered in cardio-oncology...